FDA recommendations for ANDAs based on QbD: A bioequivalence case
Transcript of FDA recommendations for ANDAs based on QbD: A bioequivalence case
FDA recommendationsfor ANDAs based on QbD:
A bioequivalence case study
44ème Congrès International SFSTP – 6 et 7 juin 2012LA CONNAISSANCE SCIENTIFIQUE AU SERVICE DE LA QUALITE PRODUITLA CONNAISSANCE SCIENTIFIQUE AU SERVICE DE LA QUALITE PRODUIT
Apports du Apports du «« QualityQuality by Designby Design »» et retours det retours d’’expexpéériences riences
Ethan StierDeputy Director of Division of Bioequivalence II
FDA, Office of Generic Drugs
Ethan Stier 144ème Congrès International SFSTP 6-7 Juin 2012
FDA recommendations for ANDAs based on QbD:
A bioequivalence case study Proposal to use pAUC metrics to assess BE of Methylphenidate
multiphasic modified release (MMR) formulations
Ethan Stier 244ème Congrès International SFSTP 6-7 Juin 2012
3
Therapeutic Equivalence
PharmaceuticalEquivalence
Bioequivalence
TherapeuticEquivalence
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
4
Therapeutic Equivalence
Generic product will have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling, and may be substituted for each otherwithout adjustment in dose or other additional monitoring
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
5
Current FDA Acceptance Criteria for BE Studies
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
6
How to show that two drugs are bioequivalent
• FDA’s regulations define BE as lack of a significant difference in rate and extent to which drug becomes available at the site of action
• For systemically active drugs– Cmax
– AUC
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
7
Current acceptance criteria for BE studies• The 90% confidence intervals of the geometric
mean test/reference (T/R) Cmax and AUC ratios should fall within the limits of 80-125%– Metrics are Cmax AUC0-t AUC∞
• We also evaluate Tmax qualitatively (not statistically) Not a continuous variable– Value determined by sampling times
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
8
A Complex Product which Meets BE Criteria but Deemed not TE
0
2
4
6
8
10
12
0 10 20 30 40
Time (hr)
Plas
ma
Con
c. (n
g/m
l)
testref
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
9
Quality Target Product Profile
ICH Q8(R2) Definition
QTPP : A prospective summary of the quality characteristics of a drug product that ideally will be achieved to ensure the desired quality, taking into account safety and efficacy of the drug product.
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
11
MMR formulation design
• Multiphasic modified release (MMR) products formulations contain an immediate-release (IR) and delayed-release (DR) and/or extended release (ER) portions, where– The IR portion is necessary for rapid onset of
activity; – The DR or ER portion is necessary to sustain
activity
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
12
Marketed MPH MMR products• Concerta® tablet
– ER core with an IR overcoat• Metadate CD® capsule
– Formulated as 30% IR, 70% ER• Ritalin LA® capsule
– ½ dose as IR beads– ½ dose as enteric-coated, DR beads
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
13
Mean plasma profilesConcerta® qd vs IR MPH tid
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
14
Clinical response throughout day following single Concerta® dose
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
15
MPH MMR products
• Given once daily, in the morning• MPH does not accumulate to steady-state• PK / PD models show that peak response
achieved at about same time as peak MPH plasma concentrations
• For Concerta®, maximal response occurs 2 hrs post-dosing, sustained throughout day
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
16
FDA Proposal for pAUC BE Metrics for MPH MMR
Formulations
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
17
Proposed BE metrics for MMR products• Propose to use 4 metrics instead of 3
– Present: Cmax AUC0-t AUC∞– Proposed: Cmax AUC0-T AUCT-t AUC∞
• AUC0-T should compare T & R exposure responsible for early onset of response
• AUCT-t should compare T & R exposure responsible for sustained response
• All metrics should met BE limits (80-125)Where T is product-specific time, t is last PK sampling time
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
18
Using AUC0-3h for BE studies of generics to MPH multiphasic products
• In fasting subjects– The IR MPH Tmax [mean ± S.D.] is 2 ± 0.5 h;
• 2 hr is also time at which maximal response [compared to placebo] is achieved;
• By 3 hr, expect that 95% of patients should achieve maximal early onset of response– Mean ± 2 S.D. = 95% of population response – 95% of subjects should achieve maximal early
onset of response by 2 h + [2 x 0.5 h] = 3 hEthan Stier 44ème Congrès International SFSTP
6-7 Juin 2012
19
Proposal for pAUC BE metrics for generics to MPH multiphasic products
• For fasting BE studiesCmax AUC0-3h AUC3h-t AUC∞
• For fed BE studiesCmax AUC0-4h AUC4h-t AUC∞
• Early pAUC should compare T & R exposure associated with response onset
• Later pAUC should compare T & R exposure associated with sustained response
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
21
For Detailed QBD examples • Quality by Design Example for Generic Modified Release
Drug Products (http://www.aaps.org/uploadedFiles/Content/Sections_and_Groups/Regional_Discussion_Groups/Sept%20presentation.pdf)
• Quality by Design for ANDAs: An Example for Modified Release Dosage Forms (http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM286595.pdf)
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
22
Summary and Conclusions• Present FDA BE study acceptance criteria may not
be adequate for some drugs formulated as MMR products
• FDA proposes using two pAUCs for BE studies of MMR products formulated to achieve rapid onset of response and sustained response– The first pAUC will compare T & R early exposure– The second pAUC will compare T& R later
exposure
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
23
Summary and Conclusions
• FDA proposes selecting the sampling time for the first pAUC to ensure that 90-95% of subjects will have achieved the optimal early onset of response
• The objective is to ensure that the proposed generic to a multiphasic MR product, once approved, will be switchable with its corresponding reference
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012
24
References
• The FDA proposed to use pAUC metrics to assess BE of methylphenidate MMR products at the FDA’s Pharmaceutical Sciences and Clinical Pharmacology Advisory Committee in April 2010
Ethan Stier 44ème Congrès International SFSTP 6-7 Juin 2012